scholarly journals Feasibility and Safety of Whole Lung Irradiation in the Treatment of Canine Appendicular Osteosarcoma

2021 ◽  
Author(s):  
Amanda Brehm ◽  
Heather Wilson‐Robles ◽  
Tasha Miller ◽  
Jill Jarvis ◽  
Michael Deveau
Keyword(s):  
Lung Irradiation ◽  
Whole Lung Irradiation

Heart-sparing volumetric modulated arc therapy for whole lung irradiation

2018 ◽  
Vol 195 (1) ◽  
pp. 77-82 ◽  
Author(s):  
Alexandros Papachristofilou ◽  
Anna-Lena Hottinger ◽  
Oliver Weinhold ◽  
Yasar-Kemal Avcu ◽  
Tobias Finazzi ◽  
...  
Keyword(s):  
Volumetric Modulated Arc Therapy ◽  
Arc Therapy ◽  
Lung Irradiation ◽  
Whole Lung Irradiation

Wilm's tumor with pulmonary metastases at diagnosis: the significance of primary chemotherapy. International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee.

1990 ◽  
Vol 8 (7) ◽  
pp. 1187-1190 ◽  
Author(s):  
J de Kraker ◽  
J Lemerle ◽  
P A Voûte ◽  
J M Zucker ◽  
M F Tournade ◽  
...  
Keyword(s):  
Pulmonary Metastases ◽  
Wilms Tumor ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Local Therapy ◽  
Stage Iv ◽  
Actuarial Survival ◽  
Preoperative Ct ◽  
Lung Irradiation ◽  
Whole Lung Irradiation

Data from patients with pulmonary metastases (PM) from Wilms' tumor at diagnosis (stage IV) were collected from six European centers. All patients were pretreated with a chemotherapy (CT) regimen consisting of vincristine (VCR), dactinomycin (AD), and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH). After nephrectomy, local therapy for residual pulmonary disease was considered to avoid whole-lung irradiation. Only four of 36 patients still had multiple inoperable metastases after preoperative CT. Thirty patients survived. Four of them were irradiated. Of the six patients who died, four died of PM, one died of abdominal recurrence, and one of therapy-related disease. Disease-free survival and actuarial survival rates are 83% with a mean follow-up of 4 years postnephrectomy.

Whole lung irradiation for completely responding pulmonary metastases in pediatric Ewing sarcoma

2020 ◽  
Vol 16 (15) ◽  
pp. 1043-1051
Author(s):  
Hagar Elghazawy ◽  
Azza Nasr ◽  
Iman Zaky ◽  
Manal Zamzam ◽  
Ahmed Elgammal ◽  
...  
Keyword(s):  
Pulmonary Metastases ◽  
Pediatric Population ◽  
Event Free Survival ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Real Value ◽  
Lung Irradiation ◽  
Whole Lung Irradiation ◽  
The Impact

Aim: Scarce data assessing the real value of whole lung irradiation (WLI) in Ewing’s sarcoma (ES) with lung-only metastasis, with published conflicting results. We studied the impact of WLI in a homogenous pediatric population. Materials & methods: Retrospective study evaluating the survival outcomes of WLI in these patients. Results: Out of 163 metastatic ES; 41 patients were eligible for WLI. 30 patients (73.1%) received WLI (+ve) while 11 patients (26.8%) did not receive WLI (-ve). Five-year event-free survival was statistically significant in WLI (+ve). Five-year pulmonary relapse-free survival showed trend for improvement with WLI (+ve), while 5-year overall survival was not statistically significant between the two arms. Conclusion: WLI added significantly to the long term clinical outcome of metastatic ES patients, with no irreversible toxicity.

scholarly journals Effects of pulmonary function of whole lung irradiation for Wilm's tumour in children.

Thorax ◽  
1982 ◽  
Vol 37 (3) ◽  
pp. 175-180 ◽  
Author(s):  
M R Benoist ◽  
J Lemerle ◽  
R Jean ◽  
P Rufin ◽  
P Scheinmann ◽  
...  
Keyword(s):  
Pulmonary Function ◽  
Lung Irradiation ◽  
Whole Lung Irradiation

Low Dose, Single Fraction, Whole Lung Irradiation for Extramedullary Hematopoiesis Associated with Myelofibrosis with Myeloid Metaplasia

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2820-2820 ◽  
Author(s):  
Hafsa M Chaudhry ◽  
Kenneth W Merrell ◽  
Ayalew Tefferi ◽  
Michelle A Neben Wittich
Keyword(s):  
Bone Marrow ◽  
Clinical Improvement ◽  
Low Dose ◽  
Symptomatic Improvement ◽  
Pleural Effusions ◽  
Single Fraction ◽  
Lung Irradiation ◽  
Whole Lung Irradiation

Abstract Introduction Polycythemia vera (PV) and Essential thrombocytosis (ET) progress to myelofibrosis (MF). Extramedullary hematopoeisis (EMH) is common in patients with primary or secondary MF, and can occur in the lungs. Pulmonary EMH can cause recurrent pleural effusions, pulmonary hypertension, and right heart failure with symptoms of dyspnea, cough, and fatigue. Low dose single fraction whole lung irradiation (WLI) has been utilized at our institution, and our preliminary report of 4 patients noted symptomatic improvement with no reported acute side effects. Here we report on a larger cohort of 57 patients as well as long term outcomes for 20 of those patients, including the original 4 patients. Methods We performed a retrospective review of 57 patients with myelofibrosis and pulmonary EMH who received single fraction WLI to a dose of 100 cGy at the Mayo Clinic from March 2001 to March 2014. Data related to the following parameters was collected: initial diagnosis, age at initial diagnosis, date of progression to myelofibrosis, initial treatment prior to radiation therapy, whole body bone marrow scan findings if available, and response to WLI. Overall survival was measured using the Kaplan Meier method. Chi-square analysis was used to evaluate predictors of response to WLI. Results The median age at first WLI was 67 years (45-84 years), and 33 patients (58%) were male. Twenty-two patients (39%) had a diagnosis of primary MF, 27 patients (47%) had PV or ET, and 8 patients (14%) had another cause of secondary MF. At the time of WLI, 27 patients (47%) were on supplemental oxygen, and 3 patients (5%) were in the intensive care unit. Hydroxyurea (n=14, 25%), JAK2 inhibitors (n=9, 16%), Anagrelide (n=3, 5%), and Thalidomide and Prednisone (n=3, 5 %) were the most frequent treatments prior to WLI. EMH was confirmed on bone scan in 38 patients (67%). In the remaining 19 patients, a diagnosis of EMH was made based on clinical impression. This included symptoms of dyspnea, cough, and fatigue, echocardiographic findings of pulmonary hypertension, and in some patients recurrent pleural effusions (n=13), positive lymph node biopsy (n=2), or thoracentesis (n=1). Twenty-eight (49%) patients had other active cardiac or pulmonary conditions that likely contributed to their clinical symptoms. These patients were receiving concurrent treatment for their other conditions. In some patients there were multiple coexisting conditions. Clinical improvement occurred in 30 patients (53%). The median time from WLI to symptomatic improvement was 10 days (1-174 days). Twenty-four patients (42%) did not have clinical improvement. Nine patients (16%) had stable symptoms, 15 patients (26%) had progressive symptoms, and 3 patients (5%) had insufficient follow up. In the group of patients with concurrent active cardiac or pulmonary conditions, 15 patients (54%) had clinical improvement following WLI. In the 29 patients who had solitary EMH, 15 (52%) patients had clinical improvement. There was no difference in response rates related to oxygen use at the time of WLI. Six patients (11%) received WLI on multiple occasions. There was no difference in the percentage of patients with positive bone marrow scans (67%) in the 2 groups. The median overall survival was 259 days for all patients. Patients who improved after WLI had a median survival of 325.5 days compared to 122.5 days for patients who did not improve. No new hematologic abnormalities temporally related to WLI were reported. Long term follow up beyond 1 year was available for 20 patients (35%). No patients developed pneumonitis or pulmonary fibrosis that was considered related to WLI. One patient received a diagnosis of an upper esophageal squamous cell carcinoma 6 years after WLI and allogeneic stem cell transplant. Conclusion Our prior study showed WLI is safe and effective in a small number of patients with isolated pulmonary EMH from MF. The current study confirms the long term safety of this approach. Our results suggest WLI may contribute to symptomatic improvement in 1/2 of patients, even in the common clinical situation of multiple coexisting cardiac and pulmonary conditions. Repeat WLI is also well tolerated and can result in symptomatic improvement. We did not find any factors that predicted response to WLI. WLI should be considered in patients who have clinically proven pulmonary EMH and associated symptoms, even in the presence of other conditions, and can be repeated safely. Disclosures No relevant conflicts of interest to declare.

Whole Lung Irradiation in Patients With Relapsed Ewing Sarcoma

2017 ◽  
Vol 99 (2) ◽  
pp. E571
Author(s):  
S. Scobioala ◽  
U. Dirksen ◽  
H. Juergens ◽  
H.T.T. Eich
Keyword(s):  
Ewing Sarcoma ◽  
Lung Irradiation ◽  
Whole Lung Irradiation

scholarly journals CD44 and Bak Expression in IL-6 or TNF-alpha Gene Knockout Mice After Whole Lung Irradiation

2008 ◽  
Vol 49 (4) ◽  
pp. 409-416 ◽  
Author(s):  
Minako SAKAI ◽  
Mayumi IWAKAWA ◽  
Yoichiro IWAKURA ◽  
Toshie OHTA ◽  
Hirohiko TSUJII ◽  
...  
Keyword(s):  
Knockout Mice ◽  
Gene Knockout ◽  
Tnf Alpha ◽  
Gene Knockout Mice ◽  
Lung Irradiation ◽  
Alpha Gene ◽  
Whole Lung Irradiation

scholarly journals The clinical efficacy of low-dose whole-lung irradiation in moderate-to-severe COVID-19 pneumonia: RTMX-20 trial

2021 ◽  
Author(s):  
C.S. Ortiz ◽  
D. Hernández ◽  
C. Trujillo ◽  
D. Calderón ◽  
P. Esqueda ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Low Dose ◽  
Lung Irradiation ◽  
Whole Lung Irradiation
Sign in / Sign up

Export Citation Format

Share Document